Breaking News, Collaborations & Alliances

Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Author Image

By: Charlie Sternberg

Associate Editor

Catalent Inc., the global CDMO recently acquired by Novo Holdings, has entered a strategic collaboration with Galapagos NV, a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications. Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters